Literature DB >> 23340870

RNA interference--a silent but an efficient therapeutic tool.

Puthucode Venkatakrishnan Ramachandran1, Savarimuthu Ignacimuthu.   

Abstract

RNA interference (RNAi) is an evolutionary conserved gene regulation pathway that has emerged as an important discovery in the field of molecular biology. One of the important advantages of RNAi in therapy is that it brings about efficient downregulation of gene expression by targeting complementary transcripts in comparison with other antisense-based techniques. RNAi can be can be achieved by introducing chemically synthesized small interfering RNAs (siRNAs) into a cell system. A more stable knockdown effect can be brought about by the use of plasmid or viral vectors encoding the siRNA. RNAi has been used in reverse genetics to understand the function of specific genes and also as a therapeutic tool in treating human diseases. This review provides a brief insight into the therapeutic applications of RNAi against debilitating diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23340870     DOI: 10.1007/s12010-013-0098-1

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   2.926


  9 in total

1.  The expanding repertoire of circular RNAs.

Authors:  Paul N Valdmanis; Mark A Kay
Journal:  Mol Ther       Date:  2013-06       Impact factor: 11.454

2.  New insights for therapeutic recombinant human miRNAs heterologous production: Rhodovolum sulfidophilum vs Escherichia coli.

Authors:  Patrícia Pereira; Augusto Q Pedro; João A Queiroz; Ana R Figueiras; Fani Sousa
Journal:  Bioengineered       Date:  2017-03-10       Impact factor: 3.269

Review 3.  The rise of regulatory RNA.

Authors:  Kevin V Morris; John S Mattick
Journal:  Nat Rev Genet       Date:  2014-04-29       Impact factor: 53.242

4.  Bioenergetics and gene silencing approaches for unraveling nucleotide recognition by the human EIF2C2/Ago2 PAZ domain.

Authors:  Mahmoud Kandeel; Abdullah Al-Taher; Remi Nakashima; Tomoya Sakaguchi; Ali Kandeel; Yuki Nagaya; Yoshiaki Kitamura; Yukio Kitade
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

5.  RPN2 Gene Confers Osteosarcoma Cell Malignant Phenotypes and Determines Clinical Prognosis.

Authors:  Tomohiro Fujiwara; Ryou-U Takahashi; Nobuyoshi Kosaka; Yutaka Nezu; Akira Kawai; Toshifumi Ozaki; Takahiro Ochiya
Journal:  Mol Ther Nucleic Acids       Date:  2014-09-02       Impact factor: 10.183

Review 6.  Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders.

Authors:  Maria Francisca Coutinho; Juliana Inês Santos; Sandra Alves
Journal:  Int J Mol Sci       Date:  2016-07-04       Impact factor: 5.923

Review 7.  Genetic Substrate Reduction Therapy: A Promising Approach for Lysosomal Storage Disorders.

Authors:  Maria Francisca Coutinho; Juliana Inês Santos; Liliana Matos; Sandra Alves
Journal:  Diseases       Date:  2016-11-09

8.  siRNA Targeting the 2Apro Genomic Region Prevents Enterovirus 71 Replication In Vitro.

Authors:  Haibing Liu; Yanyan Qin; Zhenzhen Kong; Qixiang Shao; Zhaoliang Su; Shengjun Wang; Jianguo Chen
Journal:  PLoS One       Date:  2016-02-17       Impact factor: 3.240

Review 9.  RNAi and Antiviral Defense in the Honey Bee.

Authors:  Laura M Brutscher; Michelle L Flenniken
Journal:  J Immunol Res       Date:  2015-12-21       Impact factor: 4.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.